Comparative Pharmacology
Head-to-head clinical analysis: CEFAZOLIN IN DEXTROSE versus RESPORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFAZOLIN IN DEXTROSE versus RESPORAL.
CEFAZOLIN IN DEXTROSE vs RESPORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking.
RESPORAL contains theophylline, a methylxanthine that inhibits phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cAMP and cGMP levels. It also antagonizes adenosine receptors, resulting in bronchodilation and anti-inflammatory effects.
1-2 g IV every 8 hours. For serious infections, up to 2 g IV every 6 hours.
2 mg orally twice daily
None Documented
None Documented
1.8 hours in normal renal function. Prolonged to 12-24 hours in end-stage renal disease (CrCl <10 mL/min).
Terminal half-life is 12 hours (range 10-14 h), supporting twice-daily dosing in most patients.
Renal: 80-90% unchanged by glomerular filtration and tubular secretion. Biliary: minor (<1%). Fecal: negligible.
Renal excretion accounts for 70% of elimination (30% unchanged), biliary/fecal 20%, and 10% metabolized.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic